Pyruvate kinase M2 is a poor prognostic marker of and a therapeutic target in ovarian cancer.
- Published in:
- PLoS ONE, 2017, v. 12, n. 7, p. 1, doi. 10.1371/journal.pone.0182166
- By:
- Publication type:
- Article
Works matching AU Tien-Shuo Huang
Results: 2
1
2
TET1 reprograms the epithelial ovarian cancer epigenome and reveals casein kinase 2α as a therapeutic target.
- Published in:
- Journal of Pathology, 2019, v. 248, n. 3, p. 363, doi. 10.1002/path.5266
- By:
- Publication type:
- Article